A molecularly integrated grade for meningioma

Joseph Driver, Samantha E. Hoffman, Sherwin Tavakol, Eleanor Woodward, Eduardo A. Maury, Varun Bhave, Noah F. Greenwald, Farshad Nassiri, Kenneth Aldape, Gelareh Zadeh, Abrar Choudhury, Harish N. Vasudevan, Stephen T. Magill, David R. Raleigh, Malak Abedalthagafi, Ayal A. Aizer, Brian M. Alexander, Keith L. Ligon, David A. Reardon, Patrick Y. WenOssama Al-Mefty, Azra H. Ligon, Adrian M. Dubuc, Rameen Beroukhim, Elizabeth B. Claus, Ian F. Dunn, Sandro Santagata, Wenya Linda Bi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Background: Meningiomas are the most common primary intracranial tumor in adults. Clinical care is currently guided by the World Health Organization (WHO) grade assigned to meningiomas, a 3-tiered grading system based on histopathology features, as well as extent of surgical resection. Clinical behavior, however, often fails to conform to the WHO grade. Additional prognostic information is needed to optimize patient management. Methods: We evaluated whether chromosomal copy-number data improved prediction of time-to-recurrence for patients with meningioma who were treated with surgery, relative to the WHO schema. The models were developed using Cox proportional hazards, random survival forest, and gradient boosting in a discovery cohort of 527 meningioma patients and validated in 2 independent cohorts of 172 meningioma patients characterized by orthogonal genomic platforms. Results: We developed a 3-tiered grading scheme (Integrated Grades 1-3), which incorporated mitotic count and loss of chromosome 1p, 3p, 4, 6, 10, 14q, 18, 19, or CDKN2A. 32% of meningiomas reclassified to either a lower-risk or higher-risk Integrated Grade compared to their assigned WHO grade. The Integrated Grade more accurately identified meningioma patients at risk for recurrence, relative to the WHO grade, as determined by time-dependent area under the curve, average precision, and the Brier score. Conclusion: We propose a molecularly integrated grading scheme for meningiomas that significantly improves upon the current WHO grading system in prediction of progression-free survival. This framework can be broadly adopted by clinicians with relative ease using widely available genomic technologies and presents an advance in the care of meningioma patients.

Original languageEnglish (US)
Pages (from-to)796-808
Number of pages13
Issue number5
StatePublished - May 1 2022


  • copy-number alterations
  • meningioma

ASJC Scopus subject areas

  • Clinical Neurology
  • Oncology
  • Cancer Research


Dive into the research topics of 'A molecularly integrated grade for meningioma'. Together they form a unique fingerprint.

Cite this